{
    "Clinical Trial ID": "NCT01176916",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Exemestane",
        "  Participants received exemestane (Aromasin) tablet 25 mg once daily in this study. They had previously taken tamoxifen for 2 to 3 years and switched to Aromisin in this study for completion of 5 consecutive years of adjuvant hormonal therapy."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Early invasive breast cancer (T1-4N1-3M0) confirmed by histology or cytology.",
        "  ER positive.",
        "  The patient must be postmenopausal woman.",
        "  The patient has received adjuvant Tamoxifen therapy for up to 2-3 years and will switch to receive Aromasin\u00ae treatment (The decision to prescribe Aromasin\u00ae will necessarily precede and will be independent of the decision to enroll patients in the study).",
        "Exclusion Criteria:",
        "  Following the adjuvant Tamoxifen therapy for 2-3 years and prior to receiving Aromasin\u00ae treatment, there is evidence of a local relapse or distant metastasis of breast cancer, or a second primary cancer.",
        "  Following the adjuvant Tamoxifen therapy for 2-3 years and received other aromatase inhibitors (not Aromasin\u00ae)."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Time-to-Event",
        "  An event was defined as the earliest occurrence of any of the following: 1) Loco-regional/distant recurrence of the primary breast cancer (BC) (Loco-regional recurrence was defined as any recurrence in the ipsilateral breast, chest wall or axillary lymph nodes.); 2) Appearance of a second primary or contralateral breast cancer; 3) Death due to any cause.",
        "  Time frame: 2-3 years (time for previously taking tamoxifen [prior to this study] and time for taking Aromasin [in this study] add up to 5 years)",
        "Results 1: ",
        "  Arm/Group Title: Exemestane",
        "  Arm/Group Description: Participants received exemestane (Aromasin) tablet 25 mg once daily in this study. They had previously taken tamoxifen for 2 to 3 years and switched to Aromisin in this study for completion of 5 consecutive years of adjuvant hormonal therapy.",
        "  Overall Number of Participants Analyzed: 558",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: months  NA  [1]    (NA to NA)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 38/558 (6.81%)",
        "  Angina unstable * 1/558 (0.18%)",
        "  Coronary artery disease * 1/558 (0.18%)",
        "  Autoimmune thyroiditis * 1/558 (0.18%)",
        "  Goitre * 1/558 (0.18%)",
        "  Hypothyroidism * 1/558 (0.18%)",
        "  Glaucoma * 1/558 (0.18%)",
        "  Chronic gastritis * 1/558 (0.18%)",
        "  Gastric polyps * 2/558 (0.36%)",
        "  Haemorrhoids * 1/558 (0.18%)",
        "  Tongue haemorrhage * 1/558 (0.18%)"
    ]
}